Cargando…

Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction

BACKGROUND: Reliable predictions of Cytotoxic T lymphocyte (CTL) epitopes are essential for rational vaccine design. Most importantly, they can minimize the experimental effort needed to identify epitopes. NetCTL is a web-based tool designed for predicting human CTL epitopes in any given protein. It...

Descripción completa

Detalles Bibliográficos
Autores principales: Larsen, Mette V, Lundegaard, Claus, Lamberth, Kasper, Buus, Soren, Lund, Ole, Nielsen, Morten
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194739/
https://www.ncbi.nlm.nih.gov/pubmed/17973982
http://dx.doi.org/10.1186/1471-2105-8-424
_version_ 1782147686133137408
author Larsen, Mette V
Lundegaard, Claus
Lamberth, Kasper
Buus, Soren
Lund, Ole
Nielsen, Morten
author_facet Larsen, Mette V
Lundegaard, Claus
Lamberth, Kasper
Buus, Soren
Lund, Ole
Nielsen, Morten
author_sort Larsen, Mette V
collection PubMed
description BACKGROUND: Reliable predictions of Cytotoxic T lymphocyte (CTL) epitopes are essential for rational vaccine design. Most importantly, they can minimize the experimental effort needed to identify epitopes. NetCTL is a web-based tool designed for predicting human CTL epitopes in any given protein. It does so by integrating predictions of proteasomal cleavage, TAP transport efficiency, and MHC class I affinity. At least four other methods have been developed recently that likewise attempt to predict CTL epitopes: EpiJen, MAPPP, MHC-pathway, and WAPP. In order to compare the performance of prediction methods, objective benchmarks and standardized performance measures are needed. Here, we develop such large-scale benchmark and corresponding performance measures and report the performance of an updated version 1.2 of NetCTL in comparison with the four other methods. RESULTS: We define a number of performance measures that can handle the different types of output data from the five methods. We use two evaluation datasets consisting of known HIV CTL epitopes and their source proteins. The source proteins are split into all possible 9 mers and except for annotated epitopes; all other 9 mers are considered non-epitopes. In the RANK measure, we compare two methods at a time and count how often each of the methods rank the epitope highest. In another measure, we find the specificity of the methods at three predefined sensitivity values. Lastly, for each method, we calculate the percentage of known epitopes that rank within the 5% peptides with the highest predicted score. CONCLUSION: NetCTL-1.2 is demonstrated to have a higher predictive performance than EpiJen, MAPPP, MHC-pathway, and WAPP on all performance measures. The higher performance of NetCTL-1.2 as compared to EpiJen and MHC-pathway is, however, not statistically significant on all measures. In the large-scale benchmark calculation consisting of 216 known HIV epitopes covering all 12 recognized HLA supertypes, the NetCTL-1.2 method was shown to have a sensitivity among the 5% top-scoring peptides above 0.72. On this dataset, the best of the other methods achieved a sensitivity of 0.64. The NetCTL-1.2 method is available at . All used datasets are available at .
format Text
id pubmed-2194739
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-21947392008-01-12 Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction Larsen, Mette V Lundegaard, Claus Lamberth, Kasper Buus, Soren Lund, Ole Nielsen, Morten BMC Bioinformatics Research Article BACKGROUND: Reliable predictions of Cytotoxic T lymphocyte (CTL) epitopes are essential for rational vaccine design. Most importantly, they can minimize the experimental effort needed to identify epitopes. NetCTL is a web-based tool designed for predicting human CTL epitopes in any given protein. It does so by integrating predictions of proteasomal cleavage, TAP transport efficiency, and MHC class I affinity. At least four other methods have been developed recently that likewise attempt to predict CTL epitopes: EpiJen, MAPPP, MHC-pathway, and WAPP. In order to compare the performance of prediction methods, objective benchmarks and standardized performance measures are needed. Here, we develop such large-scale benchmark and corresponding performance measures and report the performance of an updated version 1.2 of NetCTL in comparison with the four other methods. RESULTS: We define a number of performance measures that can handle the different types of output data from the five methods. We use two evaluation datasets consisting of known HIV CTL epitopes and their source proteins. The source proteins are split into all possible 9 mers and except for annotated epitopes; all other 9 mers are considered non-epitopes. In the RANK measure, we compare two methods at a time and count how often each of the methods rank the epitope highest. In another measure, we find the specificity of the methods at three predefined sensitivity values. Lastly, for each method, we calculate the percentage of known epitopes that rank within the 5% peptides with the highest predicted score. CONCLUSION: NetCTL-1.2 is demonstrated to have a higher predictive performance than EpiJen, MAPPP, MHC-pathway, and WAPP on all performance measures. The higher performance of NetCTL-1.2 as compared to EpiJen and MHC-pathway is, however, not statistically significant on all measures. In the large-scale benchmark calculation consisting of 216 known HIV epitopes covering all 12 recognized HLA supertypes, the NetCTL-1.2 method was shown to have a sensitivity among the 5% top-scoring peptides above 0.72. On this dataset, the best of the other methods achieved a sensitivity of 0.64. The NetCTL-1.2 method is available at . All used datasets are available at . BioMed Central 2007-10-31 /pmc/articles/PMC2194739/ /pubmed/17973982 http://dx.doi.org/10.1186/1471-2105-8-424 Text en Copyright © 2007 Larsen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Larsen, Mette V
Lundegaard, Claus
Lamberth, Kasper
Buus, Soren
Lund, Ole
Nielsen, Morten
Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
title Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
title_full Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
title_fullStr Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
title_full_unstemmed Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
title_short Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction
title_sort large-scale validation of methods for cytotoxic t-lymphocyte epitope prediction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194739/
https://www.ncbi.nlm.nih.gov/pubmed/17973982
http://dx.doi.org/10.1186/1471-2105-8-424
work_keys_str_mv AT larsenmettev largescalevalidationofmethodsforcytotoxictlymphocyteepitopeprediction
AT lundegaardclaus largescalevalidationofmethodsforcytotoxictlymphocyteepitopeprediction
AT lamberthkasper largescalevalidationofmethodsforcytotoxictlymphocyteepitopeprediction
AT buussoren largescalevalidationofmethodsforcytotoxictlymphocyteepitopeprediction
AT lundole largescalevalidationofmethodsforcytotoxictlymphocyteepitopeprediction
AT nielsenmorten largescalevalidationofmethodsforcytotoxictlymphocyteepitopeprediction